897732-93-3

Usage

Uses

Used in Pharmaceutical Industry:
JNJ-38431055 is used as a therapeutic agent for the treatment of cognitive deficits in neuropsychiatric disorders, specifically targeting schizophrenia and related conditions. Its application is based on its ability to improve cognitive function and working memory, providing an alternative to traditional antipsychotic medications that may have undesirable side effects.
Used in Research and Development:
In the field of neuropsychiatric research, JNJ-38431055 serves as a valuable tool for studying the role of dopamine D4 receptors in cognitive function and the pathophysiology of schizophrenia. Its use in preclinical studies aids in understanding the mechanisms by which it enhances cognitive performance and its potential synergistic effects with other treatments.
Used in Drug Development for Cognitive Enhancement:
JNJ-38431055 is utilized in the development of new drugs aimed at cognitive enhancement, particularly for patients suffering from cognitive impairments due to neuropsychiatric disorders. Its selective action on the dopamine D4 receptor offers a targeted approach to improving cognitive abilities without the broad side effect profile of some existing treatments.

Upstream product

• 832715-51-2 isopropyl 4-hydroxypiperidine-1-carboxylate 
• 1224097-06-6 (6-chloro-5-methoxy-pyrimidin-4-yl)-(6-methanesulfonyl-2-methyl-pyridin-3-yl)-amine 
• 897732-75-1 2-methyl-6-(methylsulfonyl)pyridin-3-amine 
• 897732-25-1 4-(6-chloro-5-methoxy-pyrimidin-4-yloxy)-piperidine-1-carboxylic acid isopropyl ester 

Relevant academic research and scientific papers

PROCESS FOR THE PREPARATION OF TRI-SUBSTITUTED PYRIDINE AND TRI-SUBSTITUTED PYRIMIDINE DERIVATIVES USEFUL AS GDIR AGONISTS

The present invention is directed to novel processes for the preparation of tri-substituted pyridine and tri-substituted pyrimidine derivatives, useful as glucose dependent insulinotropic receptor agonist, for the treatment of metabolic-related disorders and complications thereof, such as, diabetes and obesity.

PROCESS FOR THE PREPARATION OF TRI-SUBSTITUTED PYRIDINE AND TRI-SUBSTITUTED PYRIMIDINE DERIVATIVES USEFUL AS GDIR AGONISTS

The present invention is directed to novel processes for the preparation of tri-substituted pyridine and tri-substituted pyrimidine derivatives, useful as glucose dependent insulinotropic receptor agonist, for the treatment of metabolic-related disorders and complications thereof, such as, diabetes and obesity.

CRYSTALLINE FORMS OF 4-[6-(6-METHANESULFONYL-2-METHYLPYRIDIN-3-YLAMINO)-5-METHOXY-PYRIMIDIN-4-YLOXY]-PIPERIDINE-1-CARBOXYLIC ACID ISOPROPYL ESTER

The present invention is directed to a novel crystalline forms of 4-[6-(6- methanesulfonyl-2-methyl-pyhdin-3-ylamino)-5-methoxy-pyhmidin-4-yloxy]- piperidine-1 -carboxylic acid isopropyl ester, pharmaceutical compositions containing said crystalline form and the use of said crystalline forms in the treatment of metabolic related disorders. The present invention is further directed to processes for the preparation of the crystalline forms of 4-[6-(6- methanesulfonyl-2-methyl-pyhdin-3-ylamino)-5-methoxy-pyhmidin-4-yloxy]- piperidine-1 -carboxylic acid isopropyl ester.

PROCESS FOR THE PREPARATION OF 4- [6-(6-METHANESULFONYL-2-METHYL-PYRIDIN-3-YLAMINO) -5-METHOXY-PYRIMIDIN-4-YLOXY]-PIPERIDINE-1-CARBOXYLIC ACID ISOPROPYL ESTER

The present invention is directed to a process for the preparation of 4-[6- (6-methanesulfonyl-2-methyl-pyhdin-3-ylamino)-5-methoxy-pyrimidin-4-yloxy]- piperidine-1 -carboxylic acid isopropyl ester, useful as glucose dependent insulinotropic receptor agonist, for the treatment of metabolic-related disorders and complications thereof, such as, diabetes and obesity.

Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto

The present invention relates to certain substituted pyridinyl and pyrimidinyl derivatives of Fomula (Ia) that are modulators of metabolism. Accordingly, compounds of the present invention are useful in the treatment of metabolic-related disorders and com